Immune reconstitution in children following chemotherapy for acute leukemia

Anthony P Williams1, Jessica Bate2, Rachael Brooks1

  • 1Faculty of Medicine and Institute for Life Sciences University of Southampton Southampton UK.

Ejhaem
|July 18, 2022
PubMed

Insights

Pediatric acute lymphoblastic leukemia survivors experience prolonged immune system changes after chemotherapy. Key T-cell and memory B-cell populations remain low 18 months post-treatment, impacting infection risk.

Area of Science:

  • Immunology
  • Pediatric Oncology
  • Hematology

Background:

  • Pediatric acute lymphoblastic leukemia (ALL) treatment survival rates are high.
  • Current chemotherapy regimens are prolonged, raising concerns about long-term health effects.
  • Understanding the impact on the immune system is crucial for managing survivors.

Purpose of the Study:

  • To investigate the long-term immune effects in children treated for ALL.
  • To analyze changes in lymphocyte subsets and immunoglobulin levels post-chemotherapy.

Main Methods:

  • Longitudinal study of 116 pediatric ALL patients on the UKALL 2003 protocol.
  • Analysis of peripheral blood lymphocyte subsets (T-cells, B-cells, NK cells) and immunoglobulins.
  • Data collected at six time points during and up to 18 months after treatment completion.

Main Results:

  • Total lymphocytes remained low 18 months post-treatment.
  • CD4 T-cells were significantly reduced, while CD8 and NK cells normalized.
  • Memory B-cells remained below normal, with disrupted memory/naïve balance.
  • Immunoglobulin subclasses, particularly IgM, were reduced during and after treatment.

Conclusions:

  • Immune reconstitution varies significantly across lymphocyte compartments after ALL chemotherapy.
  • Persistent deficits in T-cells and memory B-cells may affect long-term infectious susceptibility and vaccine response.
  • Modern chemotherapy impacts pediatric immunity, necessitating ongoing monitoring and supportive care.